PIIIHealthcare · Medical Care FacilitiesThe 2 Wall Street analysts covering P3 Health Partners, Inc. hold a median 12-month price target of $18 — +311.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores P3 Health Partners, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PIII, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +311.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 May 2026 | TD Cowen | Maintains | Hold | — |
| 22 May 2026 | TD Cowen | Maintains | Hold | $3.00 → $14 |
| 15 May 2026 | Lake Street | Maintains | Buy | — |
| 15 May 2026 | Lake Street | Maintains | Buy | $4.00 → $14 |
| 2 Apr 2026 | TD Cowen | Maintains | Hold | — |
| 27 Mar 2026 | Lake Street | Maintains | Buy | — |
| 17 Nov 2025 | Lake Street | Maintains | Buy | — |
| 28 Aug 2025 | Lake Street | Assumes | Buy | $20 |
| 21 Apr 2025 | Lake Street | Maintains | Buy | — |
| 20 Nov 2024 | TD Cowen | Maintains | Hold | — |
| 1 Apr 2024 | BTIG | Downgrade | Neutral | — |
| 14 Mar 2024 | Lake Street | Maintains | Buy | — |
| 1 Sept 2023 | BTIG | Initiates | Buy | — |
| 30 June 2023 | TD Cowen | Initiates | Market Perform | — |
| 4 Jan 2022 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PIII appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, P3 Health Partners, Inc. returned −51.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 78% of US stocks
Cheaper than 90% of US stocks
Cheaper than 81% of US stocks
Higher than 48% of US stocks
Higher than 46% of US stocks
Higher than 65% of US stocks
Higher than 22% of US stocks
Higher than 8% of US stocks
Higher than 24% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
P3 Health Partners, Inc. has a market value of $904.8M and an enterprise value of $356.7M.
Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 8.6% year on year.
Net income over the same four quarters: −$216.5M, a −14.4% net margin.
Diluted earnings per share, trailing twelve months: $−33.00.
Free cash flow in the twelve months to 30 June 2026: −$130.5M.
Trailing P/E: −0.1×; forward P/E: −21.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
P3 Health Partners, Inc. employs 320 people — $4.7M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own P3 Health Partners, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
P3 Health Partners announced the appointment of Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026. He most recently served as a Chief Medical Officer overseeing clinical and value-based care programs.
Why it matters — The appointment adds a physician executive with clinical and value-based care leadership experience to P3’s leadership team.
P3 Health Partners reported second-quarter adjusted EBITDA of $54 million in its Q2 earnings call and raised its full-year 2026 outlook. The quarterly result included $45 million of favorable payer settlements and prior-year development.
Why it matters — The raised full-year 2026 outlook and the favorable payer settlements affecting quarterly results are notable for those tracking PIII's financial guidance and earnings quality.
Seeking Alpha published the Q2 2026 earnings call transcript for P3 Health Partners Inc. (PIII). The item is a transcript of the company's quarterly earnings call and contains no additional commentary beyond its publication.
Why it matters — The transcript gives PIII watchers direct access to the company's Q2 2026 earnings discussion, including management's statements.
P3 Health Partners announced its financial results for the second quarter ended June 30, 2026, reporting $54 million in adjusted EBITDA. The company stated that the quarter demonstrates the business is executing according to plan, with the core business driving improved profitability quarter over quarter and reflecting structural improvements.
Why it matters — The report signals that P3's core business is generating improved quarterly profitability, which is relevant for investors tracking the company's operational execution.
The 2 Wall Street analysts covering P3 Health Partners, Inc. have a median 12-month price target of $18, with estimates ranging from $13 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering P3 Health Partners, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks P3 Health Partners, Inc. 67 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, P3 Health Partners, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +311.9% from the last close, and Ticker Nerd's factor model ranks P3 Health Partners, Inc. 67 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering P3 Health Partners, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PIII are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $23 over the next 12 months.
P3 Health Partners, Inc. returned -51.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
P3 Health Partners Inc. Class A Common Stock represents ownership in P3 Health Partners, a patient-centered, physician-led population health management company.
The most recent item we track (Business Wire, 12 Oct 2026): "P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer". P3 Health Partners announced the appointment of Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026. He most recently served as a Chief Medical Officer overseeing clinical and value-based care programs.
P3 Health Partners Inc. Class A Common Stock represents ownership in P3 Health Partners, a patient-centered, physician-led population health management company. P3 Health Partners works with physicians, clinics, and community providers to support coordinated care delivery, care navigation, and value-based care operations across the United States. Its business focuses on enabling primary care and population health programs that aim to improve patient outcomes, enhance care coordination, and support lower-cost healthcare delivery. The company also provides administrative support, clinical operations tools, and data-enabled care management services to healthcare providers and partner networks. P3 Health Partners serves a role in the healthcare services market by helping organize provider-led care models around chronic disease management, preventive care, and community-based patient support. Founded in 2020 and headquartered in Henderson, Nevada, P3 Health Partners operates as a healthcare services platform centered on physician collaboration and integrated care delivery.
CEO Dr. Aric Coffman M.D. · 320 employees · United States · https://p3hp.org
